Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Navigating prognostic stratification and approach to TP53 -mutated myeloid neoplasms.

Current opinion in hematology - 1 Mar 2026

Badar Talha, Tefferi Ayalew, Gangat Naseema

Abstract excerpt

PURPOSE OF REVIEW: TP53- mutated ( TP53 -MT) myeloid neoplasms (MN) represent one of the most challenging disease subsets due to their distinct pathobiology, frequent association with therapy-related disease, chemo-resistant phenotype, and dismal outcomes. The prognostic impact of TP53 -MT is not uniform and is influenced by disease state, allelic burden, and co-occurring cytogenetic and molecular aberrations...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to TP53 gene
Share to Hematopoietic Stem Cell Transplantation
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Myeloproliferative Disorders

Share to Prognosis

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 41496439
DOI: 10.1097/MOH.0000000000000906

Genes

TP53
CD47

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Navigating prognostic stratification and approach to TP53 -mutated myeloid neoplasms.PMID 41496439Read ↗

Current State and Future Prospects of Diagnosis and Management of TP53-Mutated Myeloid Neoplasms.Semantic proximity Read ↗

TP53 -Mutated Myeloid Neoplasms: 2024 Update on Diagnosis, Risk-Stratification, and Management.Semantic proximity Read ↗

Breaking the guardian of the genome: TP53 dysfunction in myeloid neoplasms.Semantic proximity Read ↗

What have we learned about TP53-mutated acute myeloid leukemia?Semantic proximity Read ↗

A line in shifting sand: Can we define and target TP53 mutated MDS?Semantic proximity Read ↗

TP53 in AML and MDS: The new (old) kid on the block.Semantic proximity Read ↗

Nontransplant treatment approaches for myeloid neoplasm with mutated TP53.Semantic proximity Read ↗

Validation of the 5th edition of the World Health Organization and International Consensus Classification guidelines for TP53-mutated myeloid neoplasm in an independent international cohortSemantic proximity Read ↗

TP53 mutations in myeloid neoplasms: implications for accurate laboratory detection, diagnosis, and treatment.Semantic proximity Read ↗

TP53 mutation variant allele frequency of ≥10% is associated with poor prognosis in therapy-related myeloid neoplasms.Semantic proximity Read ↗

TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions.Semantic proximity Read ↗

TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.